Unlock instant, AI-driven research and patent intelligence for your innovation.

Stationary bed continuous production method of ezetimibe intermediate

A technology of ezetimibe and its production method, which is applied in the field of pharmaceutical synthesis, can solve the problems of high water content requirements for production equipment and raw materials, difficult recovery of catalysts, difficulty in continuous reaction, etc., and achieve the reduction of environmental pollution and the requirements for production equipment , easy to separate, the effect of continuous large-scale production

Active Publication Date: 2016-04-20
SHANXI PUDE PHARMA CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The synthesis of ezetimibe and its intermediates is mainly a homogeneous catalytic organic synthesis method using titanium tetrachloride and titanium isopropoxide as catalysts, which has high cost, environmental pollution, and high requirements for production equipment and raw material water content , Difficulty in continuous reaction, difficulty in catalyst recovery, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stationary bed continuous production method of ezetimibe intermediate
  • Stationary bed continuous production method of ezetimibe intermediate
  • Stationary bed continuous production method of ezetimibe intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] The preparation of embodiment 1 catalyst

[0057] Preparation of CAT-1:

[0058] Weigh 10 g of ZSM-5 molecular sieve (silicon-aluminum ratio Si / Al=25) and add it into 500 mL ammonium nitrate solution with a concentration of 2 mol / L, and stir in a water bath at 80° C. for 2 hours to carry out ion exchange. After repeated exchanges three times, the obtained solid sample was centrifuged, washed three times with deionized water, dried at 100°C, and calcined at 550°C for 4 hours. The obtained H-ZSM-5 molecular sieve sample was designated as CAT-1.

[0059] Preparation of CAT-2:

[0060] Weigh 10 g of ZSM-5 molecular sieve (silicon-aluminum ratio Si / Al=30) and add it into 500 mL ammonium nitrate solution with a concentration of 2 mol / L, and stir in a water bath at 80° C. for 2 hours to carry out ion exchange. After repeated exchanges three times, washed with deionized water three times, dried at 100°C, and calcined at 550°C for 4 hours, the obtained H-ZSM-5 molecular sie...

Embodiment 2

[0067] Embodiment 2 fixed-bed reactor reacts

[0068] Reaction material

[0069] According to the ratio in Table 1, compound A and compound B were respectively dissolved in an organic solvent, the temperature of the system was lowered to below -20°C, and an organic amine and a hydroxyl protecting agent were added to obtain the reaction materials as shown in Table 1.

[0070] Table 1 Reaction raw materials

[0071]

[0072] Note * : A is compound A; B is compound B.

[0073] fixed bed reactor

[0074] Catalyst 1 # ~ Catalyst 5 # After tableting, crushing, and granulation to 0.15mm ~ 0.18mm, they were used for reaction 1 # ~Reaction 5 # . Response 1 # Using a single-tube reactor with an inner diameter of 1 cm, the reaction temperature can be controlled at -30°C through shell-side heat exchange, and the temperature gradient of the catalyst bed in the test is less than 3°C. response 2 # ~Reaction 5 # Using a multi-tubular reactor, the reaction 2 # Two tubular r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a stationary bed continuous production method of an ezetimibe intermediate, i.e. 3-[(2R, 5S)-5-(4-fluorophenyl)-2-[(S)-[(4-fluorophenyl (amino)]][4-R1 alkoxyl] phenyl]methyl]-1-oxo-5-[(trimethyl silicon) oxygen]phenyl]-4-phenyl-(4S)-2-oxazolidinone. The stationary bed continuous production method is characterized by carrying out a contact reaction on a raw material containing a compound A and a compound B and a solid acid catalyst in a stationary bed reactor to prepare the ezetimibe intermediate. According to the stationary bed continuous production method of the ezetimibe intermediate, disclosed by the invention, original catalysts of titanium tetrachloride and titanium isopropylate are replaced by adopting the solid acid catalyst, and a continuous reaction is carried out in the stationary bed reactor, so that environment pollution and requirements on production equipment are reduced, a catalyst separating and recycling problem is solved, and large-scale continuous production of ezetimibe is enabled to become possible.

Description

technical field [0001] The present application relates to an ezetimibe intermediate 3-[(2R,5S)-5-(4-fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino)]][ 4-R 1 Preparation method of oxy]phenyl]methyl]-1-oxo-5-[(trimethylsilyl)oxy]phenyl]-4-phenyl-(4S)-2-oxazolidinone, belonging to field of drug synthesis. Background technique [0002] Ezetimibe is a new type of cholesterol-lowering drug, a selective cholesterol absorption inhibitor, which mainly blocks the exogenous absorption pathway of cholesterol. It inhibits the absorption of cholesterol in the gut by acting on cholesterol transporters. In addition, ezetimibe is hardly metabolized by cytochrome P450 enzymes, has few interactions with other drugs, and is safe and well tolerated. [0003] Ezetimibe, also known as Ezetimibe and Ezetimibe, was first jointly developed by Schering-Plough and Merck. On October 25, 2002, the US FDA approved the market, and the trade name is Aizeting Later, it has been listed in Canada, Japan, E...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07F7/18
CPCY02P20/584C07F7/1804
Inventor 李立忠王勇苏志强昝建强武晋姚荷云
Owner SHANXI PUDE PHARMA CO LTD